Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 01 2020
revised: 09 05 2020
accepted: 12 05 2020
pubmed: 7 6 2020
medline: 29 9 2020
entrez: 7 6 2020
Statut: ppublish

Résumé

Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year. We considered patients with LN who underwent renal biopsy followed by induction therapy between January 1970 and December 2016. LN was assessed using the International Society of Nephrology/Renal Pathology Society (2003) criteria and the National Institute of Health (NIH) activity and chronicity index. The renal outcome was CKD. Response was defined according to EULAR/European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations: We studied 381 patients (90.5% Caucasians). After 12-month therapy, 58%, 26% and 16% of patients achieved complete, partial and no response, respectively, according to EULAR/ERA-EDTA. During a median follow-up of 10.7 (IQR: 4.97-18.80) years, 53 patients developed CKD. At 15 years, CKD-free survival rate was 95.2%, 87.6% and 55.4% in patients with complete, partial and no response at 12 months, respectively (p<0.0001). CKD-free survival rates did not differ between complete and partial responders (p=0.067). Serum creatinine (HR: 1.485, 95% CI 1.276 to 1.625), eGFR (HR 0.967, 95% CI 0.957 to 0.977) and proteinuria at 12 months (HR 1.234, 95% CI 1.111 to 1.379) were associated with CKD, yet no reliable cut-offs were identified on the receiver operating characteristic curve. In multivariable analysis, no EULAR/ERA-EDTA response at 12 months (HR 5.165, 95% CI 2.770 to 7.628), low C4 (HR 1.053, 95% CI 1.019 to 1.089) and persistent arterial hypertension (HR 3.154, 95% CI 1.500 to 4.547) independently predicted CKD. Lack of EULAR/ERA-EDTA response at 12 months predicts CKD.

Identifiants

pubmed: 32503858
pii: annrheumdis-2020-216965
doi: 10.1136/annrheumdis-2020-216965
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1077-1083

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Gabriella Moroni (G)

Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy gabriella.moroni@policlinico.mi.it.

Mariele Gatto (M)

Division of Rheumatology, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Francesco Tamborini (F)

Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Silvana Quaglini (S)

Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.

Francesca Radice (F)

Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Nephrology Unit, ASST-Monza, Ospedale San Gerardo, Milano, Italy.

Francesca Saccon (F)

Division of Rheumatology, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Giulia Frontini (G)

Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Federico Alberici (F)

Nephrology Unit - Immunology Clinic, ASST Santo Paolo e Carlo - San Carlo Borromeo Hospital, Milano, Italy.

Lucia Sacchi (L)

Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.

Valentina Binda (V)

Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Barbara Trezzi (B)

Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Nephrology Unit, ASST-Monza, Ospedale San Gerardo, Milano, Italy.

Augusto Vaglio (A)

Department of Biomedical Clinical and Experimental Sciences "Mario Serio", Meyer Children's Hospital, University of Florence, Firenze, Italy.

Piergiorgio Messa (P)

Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Renato Alberto Sinico (RA)

Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Nephrology Unit, ASST-Monza, Ospedale San Gerardo, Milano, Italy.

Andrea Doria (A)

Division of Rheumatology, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH